A Prelude to a Lilly duel
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
Pfizer takes on Merck in a new checkpoint
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
